Farmecéutico y Publicista, con experiencia en el sector público y privado, asesor del Desapacho del Viceministro de Salud en temas de Transformación Digital, destacado en la Dirección de Regulación de Productos de Interés Sanitario donde he fungido como Administrador del Sistema Automatizado de Receta Digital. Formación Académica: Maestria en Transformación Digital de los Negocios Institución: Universidad Latina de Costa Rica Periodo: 2021 - Presente Licenciatura en Farmacia y Título Profesional de Doctor en Farmacia Institución: Universidad de Iberoamérica Periodo: 2014 - 2017 Dentro de las funciones en la Dirección de Regulación se encuentra la administación del Sistema Automatizado de Receta Digital, verificación de Buenas Prácticas de Manufactura de Medicamentos, Productos Naturales Medicinales y Cosméticos., evaluación de Publicidad de Productos de Interés Sanitario, colaboración en temas de normativa, entre otros.

Nacido el 28 de agosto de 1961 en la ciudad de San José. Educación primaria en el Conservatorio Castella y secundaria en el Liceo de Costa Rica, en la misma ciudad de San José. Educación superior en la Facultad de Medicina de la Ciudad de La Habana, Cuba, graduado como Doctor en Medicina en 1988. Residencia de cirugía en el Hospital Calixto García de la Ciudad de La Habana hasta 1991. Título de médico equiparado por la Universidad de Costa Rica como licenciado en medicina y cirugía. Médico asistente general y Director de la Clínica de Ticabán, Caja Costarricense del Seguro Social, provincia de Limón, Costa Rica de febrero 1995 a marzo 1996. Médico Director del Área Rectora de Salud de Talamanca, Ministerio de Salud, Región Huetar Caribe, Costa Rica de diciembre 1996 hasta octubre de 2002. De octubre de 2002 hasta la actualidad, médico Director Regional de la Región Rectora de Salud Central Este del Ministerio de Salud, con oficina en la ciudad de Cartago, Costa Rica.

Current professional activities: • Prof. emeritus internal medicine with focus on hematology, oncology & translational immunology, Johannes-Gutenberg University Mainz • Founding president and board member of the Association of Cancer Immunotherapy (CIMT) and president of the European Network for Cancer Immunotherapy (ENCI) • Board member of the high-tech cluster “Individualized Immune Intervention” (CI3) • Co-founder, scientific advisor, and supervisory board member of the companies Immugenix, Ganymed GmbH, BioNTech SE and TRON gGmbH LIFE PORTRAIT: I come from an Austrian family of scholars. I was born in Vienna in 1944 as the fourth child of Paul Huber who chairman of the Department of Surgery at the Leopold-Franzens-University in Innsbruck. After attending secondary school at the Schottengymnasium in Vienna and the Academic Gymnasium in Innsbruck, I studied medicine at Leopold Franzens University in Innsbruck. Prof. Herbert Braunsteiner trained me to be a specialist in internal medicine at the Innsbruck University Hospital, where in 1976 I qualified as a professor for internal medicine. Research and training residencies in immunology and stem cell transplantation took me to the Karolinska Institute for Tumor Biology in Stockholm, the Department of Immunology at the Wallenberg Institute in Uppsala, and the Fred Hutchinson Cancer Research Center in Seattle where I worked under the later Nobel Prize laureate Prof. Don Thomas. In 1984, I was appointed Professor of Clinical Immunobiology and Stem Cell Transplantation and head of the department of the same name at the Leopold Franzens University in Innsbruck. From 1990 to 2009, I headed the 3rd Medical Clinic at the University Medical Center of the Johannes Gutenberg University Mainz with a focus on hematology, oncology, translational immunology and stem cell transplantation. As a clinician, I set up a science-driven, innovative stem cell transplant and immunotherapy program at the University Medical Centre in Innsbruck and then developed the Mainz University Medical Center into a leading international center for immune-oncology and stem cell transplantation. I also founded a successful hematology-oncology school which filled numerous relevant professorships in Germany, Austria, the Netherlands, and Sweden. As a research manager, expert and consultant, I founded academic research structures such as the Collaborative Research Center 432 “Tumor Defense" and the clinical research group 410 "Lymphocyte Defense" both funded by the German Research Foundation. I was also founder of the first tumor vaccination center in Europe, which was built and financed by the German Cancer Aid, and founder and long-term president of the leading research network in Europe “Association of Cancer Immunotherapy (CIMT)” www.cimt.eu; president of the newly founded European umbrella organization “European Network for Cancer Immunotherapy (ENCI)” www.enci.network, of the translational oncology institute TRON gGmbH http://www.tron-mainz.de and the high-tech cluster "Individualized Immune Intervention - CI3" www.ci3.de of the German federal government. I was editor of international journals, textbooks and handbooks; a reviewer or function holder of national and international research funding organizations (Senate Commission of the German Research Foundation; advisor to the "Experimental Cancer Medicine Center" program of Cancer Research UK, the ISREC program of Swiss Science Foundation, the research commission of the German Cancer Aid; chairman of the “Commission somatic gene therapy” of the German Medical Association; curator of the Austrian Fund for the Promotion of Scientific Research and scientific advisor to all major German research institutions in the life sciences (German Cancer Research Center Heidelberg, Max Delbrück Center Berlin, Helmholtz Center for Environment and Health Munich) and the Paul Ehrlich Institute in Langen, the German regulatory authority for vaccines and biomedical drugs. For the past 22 years, I have also been an entrepreneur involved in research transfer and the founding and consulting of biotech companies. In 2001, I founded Ganymed Pharmaceuticals AG with my partners Prof. Ugur Sahin and Prof. Özlem Türeci as well as BioNTech SE http://www.biontech.de in 2008 and the non-profit translational research institute TRON gGmbH http://www.tron-mainz.de in 2009. Ganymed successfully developed clinically validated monoclonal antibodies against proprietary tumor antigens, thereby doubling the life expectancy of patients with tumors of the upper gastrointestinal tract. Ganymed was sold in 2016 to the big pharma group Astellas, which is currently testing the antibody in several approval studies. BioNTech is now a NASDAQ listed biotech company with > 4000 employees. It is one of the global leaders in the development of highly innovative mRNA-based immunotherapeutic agents against cancer and infectious diseases. BioNTech and its partner companies Pfizer and Fosun have developed the world's first approved COVID19 vaccine. These and other highly innovative drugs are currently being further developed in large-scale cooperation deals with leading pharmaceutical companies (Genentech/Roche, Sanofi, Eli Lilly, Pfizer, Bayer, Genmab, Fosun, Regeneron, and others). In addition to my entrepreneurial work, I have been an internationally active mentor for academic spin-off companies, a member of the scientific advisory boards of pharmaceutical and biotechnology companies as well as of strategic investors in Germany, UK, France, Austria, Norway, and the USA. I am an honorary member of the Austrian Academy of Sciences, recipient of honorary doctorates from the University of Innsbruck and the Johannes-Gutenberg-University in Mainz and of other awards (Federal Crosses of Merit of the FRG and the Republic of Austria, Order of Merit of the State of Rhineland-Palatinate, and the State of Tyrol ) and prizes (Future Price of the Federal Republic of Germany, Carl-Friederich-von-Weizsäcker Price of the German National Academy of Sciences, among others).